Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration

Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration

(2019) Clemens Muehlan et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Accelerated Development of the Dual Orexin Receptor Antagonist ACT-541468: Integration of a Microtracer in a First-in-Human Study

(2018) Clemens Muehlan et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Insomnia in Elderly Patients: Recommendations for Pharmacological Management

(2018) Vivien C. Abad et al.   DRUGS & AGING

Interaction potential of the dual orexin receptor antagonist ACT-541468 with CYP3A4 and food: results from two interaction studies

(2018) Marie-Laure Boof et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline

(2017) Michael J. Sateia et al.   Journal of Clinical Sleep Medicine

The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468

(2017) Alexander Treiber et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia

(2015) Anthony J. Roecker et al.   JOURNAL OF MEDICINAL CHEMISTRY

Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial

(2014) David Michelson et al.   LANCET NEUROLOGY

Motivational activation: a unifying hypothesis of orexin/hypocretin function

(2014) Stephen V Mahler et al.   NATURE NEUROSCIENCE

Häufigkeit und Verteilung von Schlafproblemen und Insomnie in der deutschen Erwachsenenbevölkerung

(2013) R. Schlack et al.   Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz

Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand?

(2013) Daniel Hoyer et al.   NEUROPEPTIDES

The natural history of insomnia: Focus on prevalence and incidence of acute insomnia

(2012) Jason G. Ellis et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Orexin receptor antagonism: an ascending multiple-dose study with almorexant

(2012) Petra Hoever et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Orexin Receptor Antagonism, a New Sleep-Promoting Paradigm: An Ascending Single-Dose Study With Almorexant

(2010) P Hoever et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effect of hypnotic drugs on body balance and standing steadiness

(2010) Monique A.J. Mets et al.   SLEEP MEDICINE REVIEWS

Pharmacokinetics, pharmacodynamics and the pharmacokinetic/ pharmacodynamic relationship of zolpidem in healthy subjects

(2009) SL de Haas et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Sleep and its disorders in aging populations

(2009) Sonia Ancoli-Israel   SLEEP MEDICINE

Epidemiological and clinical relevance of insomnia diagnosis algorithms according to the DSM-IV and the International Classification of Sleep Disorders (ICSD)

(2009) Maurice M. Ohayon et al.   SLEEP MEDICINE

Free Drug Metabolic Clearance in Elderly People

(2008) Jennifer M Butler et al.   CLINICAL PHARMACOKINETICS

Effect of intrapulmonary tetrahydrocannabinol administration in humans

(2008) L. Zuurman et al.   JOURNAL OF PSYCHOPHARMACOLOGY